NASDAQ$NPCE
Neuropace Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2021.
NeuroPace reported a 2% increase in total revenue for Q4 2021, reaching $11.0 million, with initial implant revenue increasing by 10% to $8.5 million, while replacement implant revenue decreased by 19% to $2.5 million. The company's net loss for the quarter was $10.7 million, compared to a net loss of $4.6 million in the prior year period.
- Total revenue for Q4 2021 was $11.0 million, a 2% increase year-over-year.
- Initial implant revenue for Q4 2021 increased by 10% to $8.5 million.
- Replacement implant revenue for Q4 2021 decreased by 19% to $2.5 million.
- Net loss for Q4 2021 was $10.7 million, compared to a net loss of $4.6 million in the prior year period.
Headline financials
Revenue & EPS history
Neuropace · Revenue · Quarterly
$11M
Revenue by segment
Neuropace · $1.6M total across 1 segment · Q4 2022
- DIXI Medical$1.6M—100.0%
Forward guidance
Management provided revenue guidance for Q1 2022 and full year 2022, taking a measured approach given the uncertainty surrounding COVID-19.
Tailwinds
- Total revenue of $10 million to $11 million for Q1 2022
- Initial implant revenue of $8 million to $8.5 million for Q1 2022
- Total revenue of $45 million to $48 million for full year 2022
- Initial implant revenue of $39 million to $42 million for full year 2022
- Active implanting centers to increase approximately 10% compared to 2021
Headwinds
- Uncertainty surrounding COVID-19, including the risk posed by new variants
- Potential impact of COVID-19 on hospital, physician and patient behavior
- Replacement implant revenue of $2 million to $2.5 million for Q1 2022
- Replacement implant revenue of approximately $6 million for full year 2022
- Total operating expenses of $74 million to $76 million for full year 2022, which includes approximately $8 million to $9 million of non-cash stock-based compensation expense
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
-0.7%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.0%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+37.4%
Q3 2025
Best reaction
-40.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | -1.8% | +0.8% | |
| Q4 2025 | +1.1% | +1.6% | +5.9% | |
| Q3 2025 | +37.4% | +43.1% | +74.5% | |
| Q1 2025 | +21.6% | +31.3% | -14.5% | |
| Q4 2024 | -2.4% | -15.8% | +2.6% | |
| Q3 2024 | +25.7% | +23.4% | +49.9% | |
| Q2 2024 | -1.9% | -0.4% | +4.8% | |
| Q1 2024 | -40.1% | -35.9% | -51.4% | |
| Q4 2023 | +0.8% | +2.5% | -8.4% | |
| Q3 2023 | -1.4% | +9.5% | +14.6% | |
| Q2 2023 | +9.8% | +9.8% | +103.4% | |
| Q1 2023 | +1.9% | -3.5% | -15.4% | |
| Q4 2022 | -13.3% | -7.8% | -1.9% | |
| Q3 2022 | -9.9% | -17.6% | -29.6% | |
| Q2 2022 | -3.5% | -10.2% | -26.6% | |
| Q1 2022 | +1.2% | -3.6% | -3.8% | |
| Q4 2021 | -0.9% | -7.7% | -1.2% | |
| Q3 2020 | -15.2% | -22.2% | -47.7% | |
| Q3 2021 | -15.2% | -22.2% | -47.7% | |
| Q2 2021 | -7.6% | -10.7% | -8.0% | |
| Q2 2020 | -7.6% | -10.7% | -8.0% | |
| Q1 2020 | +0.8% | +8.7% | +2.2% | |
| Q1 2021 | +0.8% | +8.7% | +2.2% | |
| Q4 2020 | +0.8% | +8.7% | +2.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro